ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LEGN vs EWTX // RSI-14 & 200D SMA MOMENTUM

Legend Biotech Corporation (NASDAQ) VS. Edgewise Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LEGN 7 — EWTX 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LEGN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LEGN VS. EWTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LEGN EWTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% -31.90% +41.80 LEGN /roic <GO>
EV/EBITDA & P/E Valuation 21.0x — — TIE /valuation <GO>
Free Cash Flow Yield 2.21% -3.41% +5.62 LEGN /fcf-yield <GO>
Operating Margin 13.90% -16.20% +30.10 LEGN /operating-margins <GO>
Net Profit Margin 10.90% 0.00% +10.90 LEGN /net-margins <GO>
Revenue Growth (YoY) 9.90% -1.10% +11.00 LEGN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 26.00 -22.26 EWTX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 3/9 +5.00 LEGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 59.2 45.7 +13.50 LEGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.04 1.10 -0.06 EWTX /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 25.0x +5.50 EWTX /forward-pe <GO>
Enterprise Scale & Market Cap $4.21B $4.22B -$17.9M EWTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LEGN REV EWTX REV LEGN GROSS % EWTX GROSS % LEGN FCF EWTX FCF
FY 2025 — $535.9M — — — -$144.1M
FY 2024 — $444.7M — — — -$110.3M
FY 2023 — $320.2M — — — -$91.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LEGN // BETA 1.04
EWTX // BETA 1.10